Drugs / BNT314
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06150183 | Nov 2023 → Aug 2026 overdue | cancer | BioNTech SE | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07079631 | Jul 2025 → Dec 2030 expected | colorectal cancer | BioNTech SE | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-04-24 | BioNTech SE | Results BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025 biontech.com ↗
The data showed anti-tumor activity, delayed tumor outgrowth and prolonged survival for the combination treatment compared to both single treatments. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-04-24 | BioNTech SE | BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025 biontech.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BNT314 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07079631 ↗ |
| Route | Intravenous | “Intravenous infusion” NCT06150183 ↗ |